325 related articles for article (PubMed ID: 31190280)
1. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar.
Paek K; Kim GW; Ahn SY; Lim JH; Jung D; Kim S; Lee JH
BioDrugs; 2019 Dec; 33(6):661-671. PubMed ID: 31549311
[TBL] [Abstract][Full Text] [Related]
3. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
4. Milestones over the development of SB3, a trastuzumab biosimilar.
Pivot X; Bondarenko I; Petit T; Curtit E
Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
[TBL] [Abstract][Full Text] [Related]
5. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
[TBL] [Abstract][Full Text] [Related]
6. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
8. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
9. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
11. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
Hutterer KM; Polozova A; Kuhns S; McBride HJ; Cao X; Liu J
BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
[TBL] [Abstract][Full Text] [Related]
12. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
[TBL] [Abstract][Full Text] [Related]
13. Trial Validates Biosimilar for Trastuzumab.
Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
[TBL] [Abstract][Full Text] [Related]
14. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
[TBL] [Abstract][Full Text] [Related]
16. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar.
Kim S; Song J; Park S; Ham S; Paek K; Kang M; Chae Y; Seo H; Kim HC; Flores M
MAbs; 2017; 9(4):704-714. PubMed ID: 28296619
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
[TBL] [Abstract][Full Text] [Related]
18. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
20. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]